Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
As biopharma’s embrace of real-world evidence (RWE) gathers speed, In Vivo looks at one company that is using a mix of prestigious academic, government and non-profit partners to build a credible foundation for acceptance of this research tool in the wider commercial space.
Latest From Leadership
Consolidation of hospital networks and professionalization of purchasing teams are putting pressure on medtech prices, and they are just two of the factors that are encouraging medtech leaders to renew their focus on spending visibility and accountability. Zero-based budgeting is a tool that could help them deliver a triple win, Patrick O’Hagan and Jason Evers of Bain & Company suggest.
Patient access, regenerative medicine and immuno-oncology feature heavily in a list of the Top 10 most read In Vivo features from 2018, highlighting the issues and disease areas that are top of mind for biopharma and medtech leaders.
"All-hands-on-deck" has been the policy pursued by the US industry association AdvaMed in recent times, as it has sought to play its part in promoting user-friendly, responsive and transparent regulation and market access for medical and digital health care technology. AdvaMed chair Nadim Yared believes that, with one or two noteworthy exceptions, there is more to come in 2019 from a largely improving medtech ecosystem globally.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Professor Sir John Bell talks to In Vivo about how the life sciences sector has evolved during his career, lessons he has learned along the way, and the biggest challenges and changes ahead for the industry in 2019.
It was inevitable that Brexit would be the key theme of an interview with Danish Medicines Agency head Thomas Senderovitz earlier this year. The senior European regulator oversees one of the agencies that has taken on new staff to help deal with the impact, in drug regulatory terms, of the vote by the UK in June 2016 to leave the European Union. Senderovitz also chairs the management group of the EU Heads of Medicines Agencies network.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.